U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H23N3O5
Molecular Weight 421.4467
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TOPOTECAN

SMILES

CC[C@@]1(c2cc3-c4c(cc5c(CN(C)C)c(ccc5n4)O)Cn3c(=O)c2COC1=O)O

InChI

InChIKey=UCFGDBYHRUNTLO-QHCPKHFHSA-N
InChI=1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1

HIDE SMILES / InChI

Molecular Formula C23H23N3O5
Molecular Weight 421.4467
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020671s021lbl.pdf

Topotecan, a semi-synthetic derivative of camptothecin (a plant alkaloid obtained from the Camptotheca acuminata tree), is an anti-tumor drug with topoisomerase I-inhibitory activity similar to irinotecan. DNA topoisomerases are enzymes in the cell nucleus that regulate DNA topology (3-dimensional conformation) and facilitate nuclear processes such as DNA replication, recombination, and repair. During these processes, DNA topoisomerase I creates reversible single-stranded breaks in double-stranded DNA, allowing intact single DNA strands to pass through the break and relieve the topologic constraints inherent in supercoiled DNA. The 3'-DNA terminus of the broken DNA strand binds covalently with the topoisomerase enzyme to form a catalytic intermediate called a cleavable complex. After DNA is sufficiently relaxed and the strand passage reaction is complete, DNA topoisomerase reattaches the broken DNA strands to form the unaltered topoisomers that allow transcription to proceed. Topotecan interferes with the growth of cancer cells, which are eventually destroyed. Since the growth of normal cells can be affected by the medicine, other effects may also occur. Unlike irinotecan, topotecan is found predominantly in the inactive carboxylate form at neutral pH and it is not a prodrug. Topotecan has the same mechanism of action as irinotecan and is believed to exert its cytotoxic effects during the S-phase of DNA synthesis. Topoisomerase I relieves torsional strain in DNA by inducing reversible single strand breaks. Topotecan binds to the topoisomerase I-DNA complex and prevents religation of these single strand breaks. This ternary complex interferes with the moving replication fork, which leads to the induction of replication arrest and lethal double-stranded breaks in DNA. As mammalian cells cannot efficiently repair these double strand breaks, the formation of this ternary complex eventually leads to apoptosis (programmed cell death). Topotecan mimics a DNA base pair and binds at the site of DNA cleavage by intercalating between the upstream (−1) and downstream (+1) base pairs. Intercalation displaces the downstream DNA, thus preventing religation of the cleaved strand. By specifically binding to the enzyme–substrate complex, Topotecan acts as an uncompetitive inhibitor. Topotecan is used for the treatment of advanced ovarian cancer in patients with disease that has recurred or progressed following therapy with platinum-based regimens. Also used as a second-line therapy for treatment-sensitive small cell lung cancer, as well as in combination with cisplatin for the treatment of stage IV-B, recurrent, or persistent cervical cancer not amenable to curative treatment with surgery and/or radiation therapy. Topotecan is sold under the trade name Hycamtin.

CNS Activity

Curator's Comment:: freely crosses the blood-brain barrier

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1028.0 nM [IC50]
3.16 µM [IC50]
0.448 µM [IC50]
1.1 µM [IC50]
33.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
HYCAMTIN

Approved Use

HYCAMTIN for injection is a topoisomerase inhibitor indicated for: • metastatic carcinoma of the ovary after disease progression on or after initial or subsequent chemotherapy. • small cell lung cancer platinum-sensitive disease in patients who progressed after first-line chemotherapy. • combination therapy with cisplatin for Stage IV-B, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment.

Launch Date

8.3315517E11
Primary
HYCAMTIN

Approved Use

HYCAMTIN for injection is a topoisomerase inhibitor indicated for: • metastatic carcinoma of the ovary after disease progression on or after initial or subsequent chemotherapy. • small cell lung cancer platinum-sensitive disease in patients who progressed after first-line chemotherapy. • combination therapy with cisplatin for Stage IV-B, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment.

Launch Date

8.3315517E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
9.29 ng/mL
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
61 ng × h/mL
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.23 h
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
65%
TOPOTECAN plasma
Homo sapiens
Doses

Doses

DosePopulationAdverse events​
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Other AEs: Leukopenia, Leukopenia...
Other AEs:
Leukopenia (grade 1, 1 patient)
Leukopenia (grade 2, 1 patient)
Leukopenia (grade 3, 7 patients)
Leukopenia (grade 4, 2 patients)
Neutropenia (grade 2, 6 patients)
Neutropenia (grade 3, 2 patients)
Neutropenia (grade 4, 1 patient)
Thrombocytopenia (grade 1, 2 patients)
Thrombocytopenia (grade 2, 1 patient)
Thrombocytopenia (grade 3, 1 patient)
Thrombocytopenia (grade 4, 2 patients)
Anemia (grade 1, 3 patients)
Anemia (grade 2, 3 patients)
Anemia (1 patient)
Sources:
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Other AEs: Leukopenia, Leukopenia...
Other AEs:
Leukopenia (grade 1, 4 patients)
Leukopenia (grade 2, 4 patients)
Leukopenia (grade 3, 3 patients)
Leukopenia (grade 4, 1 patient)
Neutropenia (grade 1, 1 patient)
Neutropenia (grade 2, 2 patients)
Neutropenia (grade 3, 1 patient)
Neutropenia (grade 4, 1 patient)
Thrombocytopenia (grade 2, 3 patients)
Thrombocytopenia (grade 3, 2 patients)
Anemia (grade 1, 4 patients)
Anemia (grade 2, 1 patient)
Anemia (grade 3, 1 patient)
Anemia (3 patients)
Sources:
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Other AEs: Leukopenia, Leukopenia...
Other AEs:
Leukopenia (grade 3, 40.7%)
Leukopenia (grade 4, 15.9%)
Neutropenia (grade 3, 31%)
Neutropenia (grade 4, 50.4%)
Thrombocytopenia (grade 3, 17.7%)
Thrombocytopenia (grade 4, 22.1%)
Anemia (grade 3, 26.5%)
Anemia (grade 4, 2.7%)
Nausea (grade 1, 31.9%)
Nausea (grade 2, 25%)
Nausea (grade 3, 5.2%)
Alopecia (grade 1, 19.8%)
Alopecia (grade 2, 22.4%)
Alopecia (grade 3, 4.3%)
Fatigue (grade 1, 22.4%)
Fatigue (grade 2, 10.3%)
Fatigue (grade 3, 5.2%)
Vomiting (grade 1, 12.1%)
Vomiting (grade 2, 19.8%)
Vomiting (grade 3, 4.3%)
Vomiting (grade 4, 0.9%)
Diarrhea (grade 1, 19%)
Diarrhea (grade 2, 13.8%)
Diarrhea (grade 3, 1.7%)
Diarrhea (grade 4, 0.9%)
Sources:
1.5 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 1.5 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 1.5 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 859
Health Status: unhealthy
Condition: ovarian cancer | small cell lung cancer
Age Group: adult
Sex: M+F
Population Size: 859
Sources:
Other AEs: Neutropenia...
Other AEs:
Neutropenia (grade 4, 58%)
Sources:
1.5 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 1.5 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 1.5 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 862
Health Status: unhealthy
Condition: ovarian cancer | small cell lung cancer
Age Group: adult
Sex: M+F
Population Size: 862
Sources:
Other AEs: Thrombocytopenia, Anemia...
Other AEs:
Thrombocytopenia (grade 4, 20%)
Anemia (grade 3-4, 11%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Anemia 1 patient
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Leukopenia grade 1, 1 patient
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Thrombocytopenia grade 1, 2 patients
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Anemia grade 1, 3 patients
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Leukopenia grade 2, 1 patient
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Thrombocytopenia grade 2, 1 patient
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Anemia grade 2, 3 patients
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Neutropenia grade 2, 6 patients
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Thrombocytopenia grade 3, 1 patient
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Neutropenia grade 3, 2 patients
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Leukopenia grade 3, 7 patients
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Neutropenia grade 4, 1 patient
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Leukopenia grade 4, 2 patients
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Thrombocytopenia grade 4, 2 patients
10.5 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 10.5 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 10.5 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Anemia 3 patients
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Neutropenia grade 1, 1 patient
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Anemia grade 1, 4 patients
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Leukopenia grade 1, 4 patients
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Anemia grade 2, 1 patient
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Neutropenia grade 2, 2 patients
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Thrombocytopenia grade 2, 3 patients
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Leukopenia grade 2, 4 patients
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Anemia grade 3, 1 patient
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Neutropenia grade 3, 1 patient
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Thrombocytopenia grade 3, 2 patients
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Leukopenia grade 3, 3 patients
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Leukopenia grade 4, 1 patient
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Neutropenia grade 4, 1 patient
8.4 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 8.4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 8.4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 54 years (range: 34-75 years)
n = 25
Health Status: unhealthy
Condition: solid tumors
Age Group: 54 years (range: 34-75 years)
Sex: M+F
Population Size: 25
Sources:
Vomiting grade 1, 12.1%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Diarrhea grade 1, 19%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Alopecia grade 1, 19.8%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Fatigue grade 1, 22.4%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Nausea grade 1, 31.9%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Fatigue grade 2, 10.3%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Diarrhea grade 2, 13.8%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Vomiting grade 2, 19.8%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Alopecia grade 2, 22.4%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Nausea grade 2, 25%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Diarrhea grade 3, 1.7%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Thrombocytopenia grade 3, 17.7%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Anemia grade 3, 26.5%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Neutropenia grade 3, 31%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Alopecia grade 3, 4.3%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Vomiting grade 3, 4.3%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Leukopenia grade 3, 40.7%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Fatigue grade 3, 5.2%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Nausea grade 3, 5.2%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Diarrhea grade 4, 0.9%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Vomiting grade 4, 0.9%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Leukopenia grade 4, 15.9%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Anemia grade 4, 2.7%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Thrombocytopenia grade 4, 22.1%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Neutropenia grade 4, 50.4%
2.3 mg/m2 1 times / day multiple, oral
Recommended
Dose: 2.3 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 2.3 mg/m2, 1 times / day
Sources:
unhealthy, 62.1 years (range: 38-86 years)
n = 116
Health Status: unhealthy
Condition: ovarian cancer
Age Group: 62.1 years (range: 38-86 years)
Sex: F
Population Size: 116
Sources:
Neutropenia grade 4, 58%
1.5 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 1.5 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 1.5 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 859
Health Status: unhealthy
Condition: ovarian cancer | small cell lung cancer
Age Group: adult
Sex: M+F
Population Size: 859
Sources:
Anemia grade 3-4, 11%
1.5 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 1.5 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 1.5 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 862
Health Status: unhealthy
Condition: ovarian cancer | small cell lung cancer
Age Group: adult
Sex: M+F
Population Size: 862
Sources:
Thrombocytopenia grade 4, 20%
1.5 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 1.5 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 1.5 mg/m2, 1 times / day
Sources:
unhealthy, adult
n = 862
Health Status: unhealthy
Condition: ovarian cancer | small cell lung cancer
Age Group: adult
Sex: M+F
Population Size: 862
Sources:
PubMed

PubMed

TitleDatePubMed
Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells.
1999 Dec
The inhibitory effects of camptothecin, a topoisomerase I inhibitor, on collagen synthesis in fibroblasts from patients with systemic sclerosis.
2001
A phase I-II trial of topotecan and gemcitabine in patients with previously treated, advanced non-small cell lung cancer (LOA-3).
2001
Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer.
2001
ICE bioassay. Isolating in vivo complexes of enzyme to DNA.
2001
Paclitaxel-based three-drug combinations for the treatment of small cell lung cancer: a review of the Sarah Cannon Cancer Center experience.
2001 Apr
New agents for induction and postremission therapy of acute myeloid leukemia.
2001 Apr
Radiosensitization of tumor-targeted radioimmunotherapy with prolonged topotecan infusion in human breast cancer xenografts.
2001 Apr 1
Unusual potency of BN 80915, a novel fluorinated E-ring modified camptothecin, toward human colon carcinoma cells.
2001 Apr 1
A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma.
2001 Apr 1
Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.
2001 Apr 15
Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer.
2001 Apr 20
A mutation in subunit B of the DNA polymerase alpha-primase complex from Novikoff hepatoma cells concomitant with a conformational change and abnormal catalytic properties of the DNA polymerase alpha-primase complex.
2001 Aug
A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line.
2001 Aug 15
Resistance to topoisomerase poisons due to loss of DNA mismatch repair.
2001 Aug 15
Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer.
2001 Feb
Clear cell carcinoma of the ovary: a remarkable case.
2001 Feb
Selective drug resistant human osteosarcoma cell lines.
2001 Feb
Evaluation of topotecan and etoposide for non-Hodgkin lymphoma: correlation of topoisomerase-DNA complex formation with clinical response.
2001 Feb 1
Novel cytotoxic 7-iminomethyl and 7-aminomethyl derivatives of camptothecin.
2001 Feb 12
P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin.
2001 Feb 15
Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells.
2001 Feb 9
The role of systemic chemotherapy in the treatment of brain metastases from small-cell lung cancer.
2001 Jan
Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage.
2001 Jan 19
CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release.
2001 Jul 12
Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.
2001 Jul 15
Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines.
2001 Jun
Oligodendroglial ganglioglioma with anaplastic features arising from the thalamus.
2001 Jun
Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study.
2001 Jun
Sodium phenylbutyrate induces apoptosis in human retinoblastoma Y79 cells: the effect of combined treatment with the topoisomerase I-inhibitor topotecan.
2001 Jun
Overview of the treatment of infant central nervous system tumors: medulloblastoma as a model.
2001 Jun-Jul
The epidermal growth factor receptor as a target for cancer therapy.
2001 Mar
Topoisomerase I targeting agents in small-cell lung cancer.
2001 Mar
Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.
2001 Mar 1
Carrier and dose effects on the pharmacokinetics of T-0128, a camptothecin analogue-carboxymethyl dextran conjugate, in non-tumor- and tumor-bearing rats.
2001 Mar 12
Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer.
2001 Mar 15
A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study.
2001 May
Phase II trial of topotecan, carboplatin, and paclitaxel as front-line therapy in suboptimal advanced epithelial ovarian cancer.
2001 May
Synthesis and biological evaluation of novel A-ring modified hexacyclic camptothecin analogues.
2001 May 10
Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study.
2001 May 15
[Interaction of topotecan--a DNA topoisomerase inhibitor--with dual-stranded polydeoxyribonucleotides. I. Dimerization of topotecan in solution].
2001 May-Jun
Advances in chemotherapy for small cell lung cancer: single-agent activity of newer agents.
2001 May-Jun
High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.
2001 Sep
Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure.
2001 Sep 1
Patents

Sample Use Guides

Ovarian cancer and small cell lung cancer: 1.5 mg/m2 by intravenous infusion over 30 minutes daily for 5 consecutive days, starting on Day 1 of a 21-day course. Cervical cancer: 0.75 mg/m2 by intravenous infusion over 30 minutes on Days 1, 2, and 3 repeated every 21 days in combination with cisplatin 50 mg/m2 on Day 1
Route of Administration: Intravenous
In Vitro Use Guide
In DC3F hamster lung fibroblasts, 2.5 uM topotecan caused redistribution of topo I to nonnucleolar regions of the nucleus.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:55:19 UTC 2021
Edited
by admin
on Fri Jun 25 21:55:19 UTC 2021
Record UNII
7M7YKX2N15
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TOPOTECAN
EMA EPAR   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
NOGITECAN
Common Name English
TOPOTECAN [INN]
Common Name English
NSC-609699
Code English
TOPOTECAN [VANDF]
Common Name English
1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-3,14(4H,12H)-DIONE, 10-((DIMETHYLAMINO)METHYL)-4-ETHYL-4,9-DIHYDROXY-, (4S)-
Systematic Name English
10-HYDROXY-9-((DIMETHYLAMINO)METHYL)-(20S)-CAMPTOTHECIN
Common Name English
TOPOTECAN [EMA EPAR]
Common Name English
HYCAMPTAMINE
Common Name English
TOPOTECAN [WHO-DD]
Common Name English
SK&F-104864
Code English
HYCAMPTIN
Brand Name English
TOPOTECAN [MI]
Common Name English
NSC-641007
Code English
SKF-104864
Code English
Classification Tree Code System Code
WHO-VATC QL01XX17
Created by admin on Fri Jun 25 21:55:20 UTC 2021 , Edited by admin on Fri Jun 25 21:55:20 UTC 2021
EMA ASSESSMENT REPORTS POTACTASOL (AUTHORISED: SMALL CELL LUNG CARCINOMA, UTERINE CERVICAL NEOPLASMS)
Created by admin on Fri Jun 25 21:55:20 UTC 2021 , Edited by admin on Fri Jun 25 21:55:20 UTC 2021
FDA ORPHAN DRUG 694519
Created by admin on Fri Jun 25 21:55:20 UTC 2021 , Edited by admin on Fri Jun 25 21:55:20 UTC 2021
EMA ASSESSMENT REPORTS HYCAMTIN (AUTHORIZED: OVARIAN NEOPLASMS, SMALL CELL LUNG CARCINOMA, UTERINE CERVICAL NEOPLASMS)
Created by admin on Fri Jun 25 21:55:20 UTC 2021 , Edited by admin on Fri Jun 25 21:55:20 UTC 2021
EMA ASSESSMENT REPORTS EVOTOPIN (WITHDRAWN: OVARIAN NEOPLASMS
Created by admin on Fri Jun 25 21:55:20 UTC 2021 , Edited by admin on Fri Jun 25 21:55:20 UTC 2021
LIVERTOX 982
Created by admin on Fri Jun 25 21:55:20 UTC 2021 , Edited by admin on Fri Jun 25 21:55:20 UTC 2021
EMA ASSESSMENT REPORTS TOPOTECAN HOSPIRA (AUTHORISED: SMALL CELL LUNG CARCINOMA)
Created by admin on Fri Jun 25 21:55:20 UTC 2021 , Edited by admin on Fri Jun 25 21:55:20 UTC 2021
EMA ASSESSMENT REPORTS TOPOTECAN ACTAVIS (AUTHORISED: SMALL CELL LUNG CARCINOMA, UTERINE NEOPLASMS )
Created by admin on Fri Jun 25 21:55:20 UTC 2021 , Edited by admin on Fri Jun 25 21:55:20 UTC 2021
NDF-RT N0000000176
Created by admin on Fri Jun 25 21:55:20 UTC 2021 , Edited by admin on Fri Jun 25 21:55:20 UTC 2021
EMA ASSESSMENT REPORTS TOPOTECAN TEVA (AUTHORIZED: OVARIAN NEOPLASMS, SMALL CELL LUNG CARCINOMA, UTERINE CERVICAL NEOPLASMS)
Created by admin on Fri Jun 25 21:55:20 UTC 2021 , Edited by admin on Fri Jun 25 21:55:20 UTC 2021
NDF-RT N0000175609
Created by admin on Fri Jun 25 21:55:20 UTC 2021 , Edited by admin on Fri Jun 25 21:55:20 UTC 2021
WHO-ATC L01XX17
Created by admin on Fri Jun 25 21:55:20 UTC 2021 , Edited by admin on Fri Jun 25 21:55:20 UTC 2021
NCI_THESAURUS C2843
Created by admin on Fri Jun 25 21:55:20 UTC 2021 , Edited by admin on Fri Jun 25 21:55:20 UTC 2021
Code System Code Type Description
DRUG CENTRAL
2707
Created by admin on Fri Jun 25 21:55:20 UTC 2021 , Edited by admin on Fri Jun 25 21:55:20 UTC 2021
PRIMARY
INN
6783
Created by admin on Fri Jun 25 21:55:20 UTC 2021 , Edited by admin on Fri Jun 25 21:55:20 UTC 2021
PRIMARY
NCI_THESAURUS
C1413
Created by admin on Fri Jun 25 21:55:20 UTC 2021 , Edited by admin on Fri Jun 25 21:55:20 UTC 2021
PRIMARY
HSDB
8213
Created by admin on Fri Jun 25 21:55:20 UTC 2021 , Edited by admin on Fri Jun 25 21:55:20 UTC 2021
PRIMARY
LACTMED
Topotecan
Created by admin on Fri Jun 25 21:55:20 UTC 2021 , Edited by admin on Fri Jun 25 21:55:20 UTC 2021
PRIMARY
MERCK INDEX
M10977
Created by admin on Fri Jun 25 21:55:20 UTC 2021 , Edited by admin on Fri Jun 25 21:55:20 UTC 2021
PRIMARY Merck Index
DRUG BANK
DB01030
Created by admin on Fri Jun 25 21:55:20 UTC 2021 , Edited by admin on Fri Jun 25 21:55:20 UTC 2021
PRIMARY
IUPHAR
7101
Created by admin on Fri Jun 25 21:55:20 UTC 2021 , Edited by admin on Fri Jun 25 21:55:20 UTC 2021
PRIMARY
EVMPD
SUB11191MIG
Created by admin on Fri Jun 25 21:55:20 UTC 2021 , Edited by admin on Fri Jun 25 21:55:20 UTC 2021
PRIMARY
ChEMBL
CHEMBL84
Created by admin on Fri Jun 25 21:55:20 UTC 2021 , Edited by admin on Fri Jun 25 21:55:20 UTC 2021
PRIMARY
WIKIPEDIA
Topotecan
Created by admin on Fri Jun 25 21:55:20 UTC 2021 , Edited by admin on Fri Jun 25 21:55:20 UTC 2021
PRIMARY
PUBCHEM
60700
Created by admin on Fri Jun 25 21:55:20 UTC 2021 , Edited by admin on Fri Jun 25 21:55:20 UTC 2021
PRIMARY
RXCUI
57308
Created by admin on Fri Jun 25 21:55:20 UTC 2021 , Edited by admin on Fri Jun 25 21:55:20 UTC 2021
PRIMARY RxNorm
MESH
D019772
Created by admin on Fri Jun 25 21:55:20 UTC 2021 , Edited by admin on Fri Jun 25 21:55:20 UTC 2021
PRIMARY
CAS
123948-87-8
Created by admin on Fri Jun 25 21:55:20 UTC 2021 , Edited by admin on Fri Jun 25 21:55:20 UTC 2021
PRIMARY
FDA UNII
7M7YKX2N15
Created by admin on Fri Jun 25 21:55:20 UTC 2021 , Edited by admin on Fri Jun 25 21:55:20 UTC 2021
PRIMARY
EPA CompTox
123948-87-8
Created by admin on Fri Jun 25 21:55:20 UTC 2021 , Edited by admin on Fri Jun 25 21:55:20 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> SUBSTRATE
Km
TRANSPORTER -> SUBSTRATE
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TRANSPORTER -> SUBSTRATE
Km
TARGET -> INHIBITOR
TRANSPORTER -> SUBSTRATE
Vmax
TRANSPORTER -> SUBSTRATE
Vmax
Related Record Type Details
METABOLITE -> PARENT
FECAL; PLASMA; URINE
Related Record Type Details
ACTIVE MOIETY